Wednesday, September 20, 2017 6:21:04 PM
Common Stock 9/14/2017 P 187625 A $1.22 (1) 212323 D
Common Stock 9/15/2017 P 127702 A $1.49 (1) 340025 D
Common Stock 9/18/2017 P 173500 A $1.75 (1) 513525 D
Common Stock 9/19/2017 P 34002 A $1.78 (1) 547527 D
He started buying after the PR was released i.e. the PR info became common knowledge releasing him of any insider trading accusations so what's in the PR that hints on why he's buying. Is it for CASI's import drug registration clinical trial application for EVOMELA being granted Priority Review? or is it for one or both of the following
Recent SPPI News
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 11/09/2023 10:00:17 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/28/2023 04:15:27 AM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 09/26/2023 09:23:08 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM